Trackers

Where every science story stands.

A discovery is rarely one day's news. Each tracker follows one question, a disease, a technology, a fight over a policy, as a dated, sourced timeline the morning letter extends, and answers where it stands right now. Every promise made along the way is kept on the record until it is kept, slips, or goes quiet.

Trackers
83
Moved this week
20
Dated beats
377
Promises tracked
23

Life Sciences & Medicine 34

Drugs finally grip the RAS cancer switch Moved this week Drugs finally grip the RAS cancer switch Where it stands · Nov 22, 2026 RAS-targeting drugs are now shrinking pancreatic and lung tumors in early trials. In 61 untreated metastatic pancreatic cancer patients, daraxonrasib plus chemotherapy shrank or cleared tumors in 60.7%, and the median time before tumors returned was 12.8 months, against five to six months typical with chemotherapy alone. The ERAS-0015 results come from a phase I trial with about four months of follow-up, and whether any of this extends survival is not yet known. Latest · Nov 22, 2026 At the EORTC-NCI-AACR symposium in Barcelona, the AURORAS-1 phase I trial of the pan-RAS molecular glue ERAS-0015 reported tumors shrinking considerably in 44% of 83 pancreatic cancer patients and 60% of 37 lung cancer patients who had already tried other treatments. A second trial gave daraxonrasib plus chemotherapy to 61 untreated metastatic pancreatic cancer patients, and tumors shrank or disappeared in 60.7%, with a median 12.8 months before progression. 1 beat Where it stands The many-fronted fight against Alzheimer's Moved this week Is there a treatment for Alzheimer's yet? Where it stands · Nov 16, 2026 The work now spans many fronts: how tau spreads, drugs that retune the brain's immune cells, blood tests and scans that catch the disease early, the blood-brain barrier, and gene maps. The largest genetic scan yet, in more than 2.8 million people, found 127 risk regions, 48 of them new, with signals pointing at the brain's immune cells. A genome scan finds associations, not causes, so none of those regions is yet a treatment target proven in people. Latest · Nov 21, 2026 Psychiatric Times reported that the drug emestedastat fell short overall in an Alzheimer's trial but signaled benefit in a subgroup. Separately, a Cambridge review linked reading for pleasure to a 33 percent lower Alzheimer's risk, an association rather than a proven cause. 52 beats 0 of 1 promise kept, 1 open Where it stands Muscarinic drugs for schizophrenia Moved this week Muscarinic drugs for schizophrenia Where it stands · Oct 14, 2026 Psychiatric Times is running pieces on muscarinic treatment in psychosis and on emerging schizophrenia mechanisms beyond dopamine, a sign the field is treating the dopamine hypothesis as incomplete. The reporting is commentary and review rather than new trial results. How well muscarinic drugs perform against existing treatments over the long term is not yet established. Latest · Nov 20, 2026 Psychiatric Times published clinical data from the Phase 3 ADEPT studies of KarXT, the xanomeline-trospium combination, in Alzheimer disease psychosis. 2 beats Where it stands Weight-loss drugs and everything else they do Moved this week Do the new weight-loss drugs do more than weight loss? Where it stands · Oct 7, 2026 GLP-1 drugs keep turning up effects that reach beyond the scale, including a possible calorie-burning brown fat mechanism, altered reward-seeking in mice, and now signs of slower biological aging. Novo Nordisk and Eli Lilly reported at a conference that patients on the drugs had aging clocks two to three years younger than placebo, up to 4 years by some measures. These are the companies' own readouts, and no one knows whether the clocks move in people who are not already sick. Latest · Nov 20, 2026 ScienceDaily reported that a UC Berkeley compound raised energy expenditure by up to 18% in mice without extra activity or higher body temperature, and that paired with GLP-1 drugs it did better than either alone. Safety and effectiveness in humans are unknown. 31 beats 0 of 1 promise kept, 1 open Where it stands A gene dimmer switch for drug-resistant epilepsy Moved this week A gene dimmer switch for drug-resistant epilepsy Where it stands · Nov 20, 2026 Three men who had lived with epilepsy for at least a decade saw monthly seizures drop by more than 90 percent in a pilot chemogenetic gene therapy trial, and one stayed seizure-free for a year. The evidence is three patients in an early trial. Whether the effect holds in larger groups and over longer follow-up is not known. Latest · Nov 20, 2026 SingularityHub reported that three men with epilepsy for at least a decade saw monthly seizures fall by more than 90 percent in a pilot trial, and one stayed seizure-free for a year. The team delivered a gene into the hippocampal patch where seizures began, and the protein it makes turns that region's activity down when an FDA-approved drug activates it. Dimitri Kullmann of University College London, who was not involved, said it has caused a lot of excitement in the field. 1 beat Where it stands CAR-T cells reset autoimmune disease Moved this week CAR-T cells reset autoimmune disease Where it stands · Nov 20, 2026 CAR-T cell therapy is showing early benefit in autoimmune disease. In a small Mayo Clinic trial of stiff person syndrome, patients walked and worked again after one round of CAR-T cells. These are small early trials, and how long the benefit lasts is not yet known. Latest · Nov 20, 2026 The Optimist Daily reported that after one round of CAR-T cells in a small Mayo Clinic trial for stiff person syndrome, Shari St. Germain walked for seven minutes on the treadmill and Jonathan Walden returned to work. 1 beat Where it stands Stem cells with a bone-marrow address for osteoporosis Moved this week Stem cells with a bone-marrow address for osteoporosis Where it stands · Nov 16, 2026 A first-in-human trial in Cell gave ten women over 50 with advanced osteoporosis a single infusion of their own stem cells coated in a sugar that steers them to bone marrow. Fractures across the group fell from an average of eight per year to 0.5 per year over two years. Ten patients is a very small group, there was no control arm described, and where the cells went after infusion was not tracked. Latest · Nov 16, 2026 A first-in-human trial in Cell gave ten women over 50 with advanced osteoporosis one infusion of their own mesenchymal stem cells coated in a sugar that acts as a return address for bone marrow. Fractures fell from an average of eight per year to 0.5 per year over two years, bone-tissue area rose about 70 percent at four months, and patients reported 34 percent less bone pain. Co-author Robert Sackstein holds intellectual-property rights to the cell-engineering technology. 1 beat Where it stands AI reading heart disease from routine ECGs Moved this week AI reading heart disease from routine ECGs Where it stands · Sep 22, 2026 An AI model trained on millions of patients read ordinary ECGs from 67,000 people and correctly flagged 81 percent of heart failure cases and 90 percent of heart valve disease cases, catching conditions that normally hide until a cardiac arrest reveals them. The model has been validated on a large retrospective dataset. It has not yet been shown to change patient outcomes in prospective clinical use. Latest · Nov 15, 2026 UC Berkeley researchers trained an AI on more than 440,000 Swedish electrocardiograms matched to death certificates and tested it on records from the United States and Taiwan. It picked out a group with a 7 percent annual sudden-death rate, against 4.6 percent for the usual ejection-fraction screen, and flagged thousands of people current guidelines would class as low risk. It is a screening result, with no change in anyone's care reported. 3 beats Where it stands Pennsylvania's measles outbreak Active Pennsylvania's measles outbreak Where it stands · Oct 20, 2026 Pennsylvania health officials issued an alert about congenital measles, something the US has not seen for decades, Ars Technica reported. The alert follows the state's earlier outbreak coverage. How many infants are affected and whether the outbreak is slowing are not yet known. Latest · Nov 12, 2026 STAT reported that the U.S. may soon lose its measles elimination status. 2 beats Where it stands A clot-stopping stroke drug that spares the bleeding Active A clot-stopping stroke drug that spares the bleeding Where it stands · Nov 11, 2026 The FDA has approved Bayer's Sunharbo, the first of the factor XIa inhibitor class, to prevent recurrent stroke, which hits roughly 20% of stroke survivors. The drug is meant to prevent clots without raising bleeding risk. How it performs in everyday use, beyond the trials behind the approval, is not yet known. Latest · Nov 11, 2026 STAT reported that the FDA approved Bayer's Sunharbo, the first of a new class of drugs meant to prevent clots without raising bleeding risk, for the roughly 20% of stroke survivors who have a second stroke. 1 beat Where it stands Reprogramming immune cells inside the body Active Reprogramming immune cells inside the body Where it stands · Nov 9, 2026 MIT researchers built fat-based nanoparticles that carry messenger RNA into natural killer cells inside the body, and in mice the resulting CAR NK cells eliminated tumors made of cancerous T cells and reversed liver damage in a model of autoimmune hepatitis. The FDA has approved seven CAR T therapies in the past decade, all made by the slower take-out-and-return route. No human has received the in-body approach, and it is not known whether the particles can reach and reprogram enough cells in larger animals. Latest · Nov 9, 2026 Daniel Anderson's lab at MIT reported in Nature Biotechnology that fat-based nanoparticles carrying messenger RNA programmed natural killer cells inside mice. The resulting CAR NK cells eliminated tumors made of cancerous T cells and reversed liver damage caused by T cells attacking healthy tissue, a model of autoimmune hepatitis. 1 beat Where it stands Why big dogs age faster Active Why big dogs age faster Where it stands · Nov 9, 2026 Researchers analyzing DNA methylation across the genomes of 894 dogs in the Dog Aging Project found a broad loss of methylation with age, especially in mobile jumping-gene sequences called transposons. More than 40% of LINE1-associated genome regions lost methylation as dogs aged, and LINE1 activity may explain part of the size and lifespan pattern. The authors say it is not the whole explanation. Latest · Nov 9, 2026 ScienceAlert reported that researchers analyzing DNA methylation in 894 dogs from the Dog Aging Project saw methylation decline with age, especially in transposons. More than 40% of LINE1-associated genome regions lost methylation as dogs aged, and senior author Noah Snyder-Mackler noted dogs are a useful model for aging in people. 1 beat Where it stands Treating and preventing long COVID Active Can long COVID be treated or prevented? Where it stands · Nov 7, 2026 Two randomized trials found Paxlovid cut the risk of developing long COVID by 40 percent within three months and metformin by around half at six months. For people who already have it, the RECOVER cohort of nearly 1,020 adults found 50% had improved by three years, but fewer than 20% of those with multisystem symptoms did. A new study found Paxlovid did not help existing symptoms, and no treatment has yet been shown to speed recovery. Latest · Nov 7, 2026 A study in Annals of Internal Medicine followed nearly 1,020 people from the NIH-funded RECOVER Adult Study and found 36% had improved at two years and 50% at three, with 26% reporting no symptoms at all. About 60% of patients whose main symptom was lost taste or smell improved, against fewer than 20% of those with symptoms across several body systems. 5 beats Where it stands Bones as a source of anti-aging signals Active Bones as a source of anti-aging signals Where it stands · Nov 6, 2026 Researchers at Southern Medical University in Guangzhou found that bone loading extended the median lifespan of old mice by 9.4 percent, about 80 days. Destroying the PIEZO1 channel in adult mouse bone cells cut median lifespan by about 11 percent in females and 13 percent in males, and PIEZO1 also falls with age in human bone. The load was applied to anaesthetized mice by a device, and nobody has shown the same effect in people. Latest · Nov 6, 2026 Researchers at Southern Medical University in Guangzhou reported that rhythmically loading the shinbones of anaesthetized mice, starting at 20 months, raised median lifespan 9.4 percent and improved strength, coordination and memory. Plasma from treated mice gave other old mice some of the benefit, and the protein PEDF, raised in the blood by bone loading, improved cognitive and physical performance when injected. 1 beat Where it stands A cochlear implant for vision Active Can an implant give sight back in macular degeneration? Where it stands · Sep 4, 2026 Science Corporation's PRIMA retinal implant, a chip smaller than a grain of rice paired with camera-mounted glasses, won European approval for commercial sale, and a 38-patient trial across five countries produced an average gain of 25.5 letters on a standard eye chart. Patients have read a novel and done crossword puzzles, though CEO Max Hodak described the current vision as like looking through a straw. The planned US launch, as soon as 2027, has not happened. Latest · Nov 5, 2026 MIT Technology Review reported that the PRIMA retinal implant, paired with camera-equipped glasses, helped people with geographic atrophy, a form of macular degeneration affecting over 5 million people. After training, more than 80 percent of recipients could read, do crosswords and use their phones. 4 beats Where it stands Clearing the brain's waste: the glymphatic drain Active Clearing the brain's waste: the glymphatic drain Where it stands · Nov 3, 2026 A University of Oulu team found that a nitric oxide pill under the tongue plus 40 minutes on a gently vibrating mattress raised blood beta-amyloid 42 by 35 percent on average in 29 healthy adults, a sign of protein leaving the brain. It was one session in people without Alzheimer's, and it is not known whether it clears anything from a diseased brain or helps patients. Latest · Nov 3, 2026 New Scientist reported that Vesa Kiviniemi's team at the University of Oulu found a nitric oxide pill plus a vibrating mattress raised blood beta-amyloid 42 by 35 percent in 29 adults without Alzheimer's. Tuomas Lilius of the University of Helsinki, who was not involved, called it a substantial acute effect. 1 beat Where it stands Prime editing reaches a patient with Wilson disease Active Prime editing reaches a patient with Wilson disease Where it stands · Oct 25, 2026 Prime Medicine has dosed the first person with an intravenous prime-editing infusion for Wilson disease, the first known use of the technique inside a human body. First results are due in 2027. No outcome number has been reported yet, so whether it works and is safe in people is not known. Latest · Oct 25, 2026 The Bright Side reported that Prime Medicine dosed the first person with an intravenous prime-editing infusion for Wilson disease, the first known use of the technique inside a human body, with first results due in 2027. 1 beat 0 of 1 promise kept, 1 open Where it stands A painted-on liquid for childhood cavities Active A painted-on liquid for childhood cavities Where it stands · Oct 28, 2026 A University of Michigan-led Phase III trial in JAMA Pediatrics enrolled 830 children under 6 and found 38% silver diamine fluoride stopped decay in 54.0% of treated lesions at six months, against 22.5% with a placebo. Treatment-related adverse events were similar, 47.3% with the liquid and 43.3% with placebo. The silver permanently darkens the decayed part of the tooth, and a regulatory approval is not confirmed because no drug application is known to have been filed. Latest · Oct 28, 2026 Good News Network and The Bright Side covered the University of Michigan-led Phase III trial of 830 children under 6 in Michigan, New York and Iowa. Decay stopped in 54.0% of lesions painted with 38% silver diamine fluoride, against 22.5% with a placebo, at six months. The Bright Side noted that claims approval may be imminent are unconfirmed. 1 beat Where it stands The expanding reach of mRNA vaccines Active Can the technology behind the COVID vaccines fight cancer too? Where it stands · Oct 25, 2026 The FDA approved mFlusiva, Moderna's mRNA seasonal flu vaccine for adults 50 and older. In the Phase 3 INTerpath-001 trial of 1,137 melanoma patients, intismeran cut the risk of recurrence or death by 42 percent, with 82.2 percent cancer-free at two years against 70.0 percent on pembrolizumab alone. Merck and Moderna are talking to regulators. Whether the vaccine helps patients live longer is not known, because overall survival has not met the trial's prespecified boundary. Latest · Oct 26, 2026 ScienceAlert reported that among patients still cancer-free six months after starting treatment, intismeran plus Keytruda cut the risk of recurrence or death by 58 percent. Georgina Long of Melanoma Institute Australia described the vaccine as a personalized "wanted poster" for the immune system. Reporting from the ESMO meeting said the vaccine is not yet available in Australia or the United States and that regulatory review could take several years depending on the country. At ESMO, James Larkin of the Royal Marsden said the approach may apply to other tumor types. 7 beats 0 of 2 promises kept, 2 open Where it stands The brain cells that keep memories alive Active Which brain cells decide whether a memory lasts? Where it stands · Sep 4, 2026 Astrocytes, long treated as scaffolding for neurons, look like active gatekeepers of which memories survive. Researchers at the Institute of Basic Science found that mice engineered without the protein ankyrin-2 in their astrocytes formed memories normally but lost all long-term recall within two weeks, and they built a light-activated tool that restored the function in living mice. This is animal and lab work, with no evidence yet that it runs the same way in people. Latest · Oct 22, 2026 Neuroscience News reported that astrocytes, long treated as one uniform population, include a subtype marked by CD51 that builds synapses and rewires memory circuits. In mice, the same subtype helped motor function recover after stroke. 8 beats Where it stands Optogenetics leaves the lab for patients Active Optogenetics leaves the lab for patients Where it stands · Oct 21, 2026 Optogenetics won the 2026 Nobel Prize in physiology or medicine for Karl Deisseroth, Peter Hegemann and Georg Nagel, and its first clinical use is in vision lost to retinitis pigmentosa. In the PIONEER trial, seven of ten patients showed improved light sensitivity and benefit grew over about five years in responders, though the vision is partial and blurry. Larger trials have not yet shown how many patients benefit. Latest · Oct 21, 2026 SingularityHub reported on the PIONEER trial, in which people with retinitis pigmentosa received an injection installing a light-sensitive algae protein in their retinas. Seven of ten patients showed improved light sensitivity, and about half could reach for and touch objects while wearing pulsed-light goggles. Responders kept improving over roughly five years. The sight was partial and blurry, with a narrow field of view. 4 beats Where it stands Gene therapy for inherited blindness Active Gene therapy for inherited blindness Where it stands · Oct 5, 2026 A Michigan State University team reported that a single injection of a virus carrying a working CaBP4 gene stopped blindness from progressing in whippets and improved vision, especially in dim light. The treated retinas also expanded the layer that holds the visual connectors, a repair many researchers had thought impossible in adult mammals. The condition is rare and the work is in dogs, so whether it works in people remains untested. Latest · Oct 17, 2026 The Bright Side reported that three adults given a one-time gene therapy for a rare inherited blindness still showed visual gains at 24 months. Only six patients have been treated and Phase 3 has not yet dosed. 2 beats Where it stands Ending hepatitis C Active Ending hepatitis C Where it stands · Oct 15, 2026 The RESOLVE trial, published in The Lancet and led by Dr Rakesh Aggarwal, found eight weeks of sofosbuvir-velpatasvir cleared hepatitis C in 410 of 415 people who returned for testing (98.8 percent), against 397 of 401 on the standard twelve weeks (99.0 percent). It enrolled 880 untreated adults without cirrhosis at five Indian hospitals, and guidelines have not changed. People with cirrhosis, HIV or injection drug use were not studied, and whether shorter courses improve completion is not yet measured. Latest · Oct 15, 2026 The RESOLVE trial, published in The Lancet and led by Dr Rakesh Aggarwal, reported that eight weeks of sofosbuvir-velpatasvir cleared hepatitis C in 410 of 415 people who returned for testing, 98.8 percent, against 397 of 401 on the standard twelve weeks, 99.0 percent. The trial enrolled 880 untreated adults without cirrhosis at five public hospitals in Lucknow, New Delhi and Varanasi. 1 beat Where it stands Stopping pancreatic cancer before it starts Active Stopping pancreatic cancer before it starts Where it stands · Oct 14, 2026 Cancer interception is emerging as its own field, aimed at halting abnormal growths before they become tumours. In one vaccine trial, roughly 90 percent of participants with pancreatic abnormalities generated immune cells better able to recognize mutated cells. Whether that immune response prevents cancer in people is not yet known. Latest · Oct 14, 2026 SingularityHub reported that in one cancer-interception vaccine trial, roughly 90 percent of participants with pancreatic abnormalities generated immune cells better able to recognize mutated cells. 1 beat Where it stands Regrowing cartilage lost to osteoarthritis Active Can worn-out joint cartilage be regrown? Where it stands · Sep 4, 2026 Stanford researchers traced age-related cartilage loss to a single enzyme, 15-PGDH, and found that blocking it regrew worn cartilage in old mice and prevented arthritis entirely in young mice given the mouse equivalent of a torn ACL. A University of Colorado Boulder team separately reported an injection that returned arthritic animal joints to a healthy state within four to eight weeks. No person has been treated, and the enzyme is active body-wide, so safety is unsettled. Latest · Oct 14, 2026 ScienceAlert reported that an FDA-approved drug could be repurposed to relieve osteoarthritis pain and protect cartilage. 3 beats Where it stands Menin and the aging brain's memory Active Menin and the aging brain's memory Where it stands · Oct 13, 2026 Restoring the protein Menin in older mice improved memory, balance, bone mass and skin thickness within 30 days, and the amino acid D-serine improved learning and memory in three weeks. The work dates from 2023 and was done in mice. Whether Menin or D-serine does anything comparable in people is not known. Latest · Oct 13, 2026 ScienceDaily reported that restoring Menin in older mice improved memory, balance, bone mass and skin thickness within 30 days, and that the amino acid D-serine improved learning and memory in three weeks, work from 2023 that is still in mice. 1 beat Where it stands Jonathan the tortoise and the genes of a long life Active Jonathan the tortoise and the genes of a long life Where it stands · Oct 9, 2026 Researchers led by the longevity nonprofit Kallel sequenced the genome of Jonathan, a 194-year-old Aldabra giant tortoise on St. Helena, and found 287 unique gene variants tied to DNA repair, lower inflammation, insulin regulation and cancer suppression. The switches controlling DNA repair and metabolism looked very similar to those of younger giant tortoises, though the epigenome usually drifts with age. It is one animal with an estimated age, so what the pattern means for other species is not known. Latest · Oct 9, 2026 Researchers led by the longevity nonprofit Kallel reported in Science Advances that Jonathan, a 194-year-old Aldabra giant tortoise, carries 287 unique gene variants tied to DNA repair, lower inflammation, insulin regulation and cancer suppression. The gene switches controlling DNA repair and metabolism in his epigenome looked very similar to those of younger giant tortoises, the first giant-tortoise epigenome on record. 1 beat Where it stands Growing human brain tissue inside mouse brains Active Growing human brain tissue inside mouse brains Where it stands · Sep 26, 2026 Scientists have begun replacing sections of the mouse cortex with human brain tissue, an early step toward chimeric brains meant to model neurological disorders directly. PsyPost reported the swap on 2026-09-26, without yet detailing how much of the circuit was human or how it functioned inside a living mouse. It remains unknown how closely these chimeric circuits reproduce a human brain's actual disease processes. Latest · Oct 7, 2026 Nature published a piece arguing that brain organoids grafted into mice that lack a cortex will advance human brain research. 4 beats Where it stands Transplanted hearts take on their new host's age Active Transplanted hearts take on their new host's age Where it stands · Oct 4, 2026 Nature reported that months after transplant, DNA methylation in heart tissue moved toward the recipient's biological age instead of the donor's. A Harvard Medical School mouse preprint now shows the same pattern in both directions: older hearts in younger mice read as younger, and younger hearts in older mice aged faster. The authors suggest donor age limits could one day loosen, but the mouse work is not peer reviewed, and whether the shift improves outcomes for patients has not been established. Latest · Oct 4, 2026 A Harvard Medical School team led by Jesse Poganik reported in a bioRxiv preprint, not yet peer reviewed, that after four to six months, older hearts transplanted into younger mice read as biologically younger and younger hearts in older mice showed signs of faster aging. A quote in a weekly roundup said the group saw the same effect in human transplant recipients, with some but not all functional measures tracking the prediction. 2 beats Where it stands REM sleep and long-term disease risk Active REM sleep and long-term disease risk Where it stands · Sep 24, 2026 A study found people who got more REM sleep had a lower risk of 83 diseases, ScienceDaily reported. This is a headline-level finding so far, and the underlying study's population, methodology and effect sizes are not yet fully known. Latest · Sep 24, 2026 A study found people who got more REM sleep had a lower risk of 83 diseases, ScienceDaily reported. 1 beat Where it stands How pregnancy, puberty and menopause reshape the brain Active How pregnancy, puberty and menopause reshape the brain Where it stands · Sep 21, 2026 A team led by cognitive neuroscientist Sophie van 't Hof at Amsterdam University Medical Center scanned more than 1,000 people repeatedly across puberty, pregnancy and menopause and found each phase left a distinct signature: gray matter loss sped up during puberty and pregnancy, consistent with active brain reorganization, while menopause instead paused the brain's normal gradual shrinkage. Participants self-reported their menopause stage and were not tested for hormone levels, so whether falling estrogen and prog Latest · Sep 21, 2026 A team led by Sophie van 't Hof at Amsterdam University Medical Center scanned the brains of more than 1,000 people repeatedly across puberty, pregnancy and menopause and found gray matter loss sped up during puberty and pregnancy, consistent with active reorganization, while the usual gradual shrinkage stopped entirely once menopause began. 1 beat Where it stands Lifestyle trials against dementia Active Can exercise and brain training lower dementia risk? Where it stands · Sep 7, 2026 LatAm-FINGERS, a two-year trial of at-risk older adults across 11 Latin American countries, published its full results in The Lancet: structured coaching in exercise and diet, adapted locally in each country rather than simply translated, improved cognition 55% more than general health advice alone. Lead author Lucia Crivelli said the program was built to be practical, affordable and feasible as a public health strategy. It is not yet known whether the gains hold once the coaching stops or translate into fewer deme Latest · Sep 7, 2026 The LatAm-FINGERS trial, published in The Lancet, found that older adults across 11 Latin American countries who received structured coaching improved cognition 55% more than a control group given only general health advice, with country working groups swapping in local forms of exercise like salsa and tango and local foods like avocado, quinoa and chia for the MIND diet. 4 beats Where it stands Resetting the body's aging immune cells Active Can the aging immune system be reset? Where it stands · Sep 4, 2026 Stanford researchers found that aging jams the receptor macrophages use to clear out spent immune cells, letting inflammation leak into organs throughout the body. Blocking that one receptor, EP2, in aged mice restored 59 of 71 previously abnormal blood proteins to youthful levels, along with leaner bodies, better grip strength and sharper memory, and the same stuck pattern turned up in older human liver tissue. Blocking EP2 in a person has never been tried. Latest · Sep 4, 2026 A Stanford team led by Katrin Andreasson found that tissue-resident macrophages lose the ability to clear a second immune cell type as animals age, driving body-wide inflammation, and blocking a single receptor on those macrophages in mice produced leaner bodies, sharper memory, stronger hearts and muscles, and younger tissue in the brain, liver, spleen, bone marrow, kidney and colon. 4 beats Where it stands Switching mammal regeneration back on Active Can mammals be made to regrow tissue instead of scarring? Where it stands · Sep 4, 2026 The machinery for regrowing tissue looks silenced in mammals rather than lost. Researchers showed the growth factor FGF2 can redirect scar-forming cells toward regeneration, and mice regrew bone, joint and ligament tissue, building on earlier work that restarted ear regeneration by switching a single gene back on. Epigenetic editing has entered human trials for muscular dystrophy, but the regeneration results themselves are still in mice. Latest · Jun 27, 2026 Epigenetic editing that switches genes on and off without changing the DNA sequence entered human trials for muscular dystrophy. 7 beats Where it stands

Natural Sciences 19

Voyager 1's long road out Moved this week Voyager 1's long road out Where it stands · Nov 21, 2026 On November 18, Voyager 1 became the first spacecraft to reach one light-day from Earth, about 16.1 billion miles. A command now takes 24 hours to arrive and the reply another 24. The probe has sent no scientific or engineering data since November 14, and engineers are investigating a communication problem, so how long it keeps working is not known. Latest · Nov 21, 2026 Voyager 1 became the first spacecraft to reach one light-day from Earth on November 18 at 2:16 a.m. PST, about 16.1 billion miles away. NASA's Jet Propulsion Laboratory received a signal from it 24 hours after the crossing, though the probe has sent no science or engineering data since November 14. 1 beat Where it stands AI and the proof of the Riemann hypothesis Moved this week AI and the proof of the Riemann hypothesis Where it stands · Nov 21, 2026 Levent Alpoge at Anthropic says AI helped him prove the Riemann hypothesis, and one mathematician called it the holy grail of the field if correct. The proof runs over 250,000 pages and has not been reviewed. Whether it is correct is not known. Latest · Nov 21, 2026 New Scientist reported that Levent Alpoge at Anthropic says AI helped him prove the Riemann hypothesis. The proof is over 250,000 pages and has not been reviewed, so the checking has barely begun. 1 beat Where it stands The SuperAgers and their protected memory Moved this week Why do some people keep a sharp memory into their nineties? Where it stands · Sep 4, 2026 A University of Chicago and TGen team compared 142 SuperAgers, people in their eighties and nineties with memory as sharp as someone decades younger, to 89 cognitively average older adults and found the two groups genetically indistinguishable on the APOE gene and three polygenic risk scores. Studies in Sardinia and in Rugao, China point instead to daily movement, personal autonomy, low stress and social ties. What actually protects those memories is still unidentified. Latest · Nov 15, 2026 A Stanford Medicine team compared 110 people with Alzheimer's and 180 SuperAgers over 75 using resting-state fMRI and built a single ARC score from the connections that separated them. In 1,315 adults with no cognitive impairment followed for mostly five to six years, those whose scans looked more Alzheimer's-like declined faster and were more likely to develop Alzheimer's or mild cognitive impairment. 6 beats Where it stands A possible sixth dwarf planet beyond Pluto Moved this week A possible sixth dwarf planet beyond Pluto Where it stands · Nov 15, 2026 Astronomer Matthew Holman found 2026 ED138, roughly 1,000 kilometers across, in Rubin Observatory data on October 13. Mario Jurić called it the largest trans-Neptunian object found in about 20 years, turned up while the telescope was still being commissioned. Whether it will be formally classed as a dwarf planet is not yet known. Latest · Nov 15, 2026 ScienceDaily reported that astronomer Matthew Holman found 2026 ED138, roughly 1,000 kilometers across, in Rubin Observatory data on October 13. Mario Jurić called it the largest trans-Neptunian object found in about 20 years, discovered while the telescope was still being commissioned. 1 beat Where it stands Black holes too massive for the young universe Moved this week How did the first black holes get so big so fast? Where it stands · Sep 4, 2026 Telescopes keep finding black holes from the universe's first billion years that already hold billions of times the mass of the sun. The Euclid telescope found 31 of the oldest quasars ever detected, and co-author Joseph Hennawi said astronomers do not yet understand how they grew so massive so fast. No accepted mechanism explains that growth, so the fossil record is running well ahead of the theory. Latest · Nov 15, 2026 ScienceDaily reported that ESA's Euclid telescope found 31 early quasars, including two that set the record for the earliest ever seen, each shining as bright as a trillion Suns when the universe was 670 million years old. Euclid is picking up fainter quasars that earlier searches missed, and lead author Daming Yang of Leiden University called how they formed and grew so quickly one of the greatest mysteries in astrophysics. 9 beats Where it stands The orexin discovery reshaping narcolepsy treatment Active The orexin discovery reshaping narcolepsy treatment Where it stands · Nov 13, 2026 Stanford's Emmanuel Mignot is sharing the 2026 Albert Lasker Basic Medical Research Award for discovering in 1999 that orexin governs wakefulness. The discovery has now reached patients: oveporexton, the first orexin agonist, is prescribable in the US for adults with narcolepsy type 1. It is not yet known how far orexin-based treatment can extend to the much larger population of people with ordinary insomnia. Latest · Nov 14, 2026 STAT reported that Takeda's Orzeyful, the first narcolepsy treatment aimed at the underlying cause, is now available in the U.S. after the DEA cleared its last regulatory hurdle. The list price is $16,500 per 60-tablet bottle. 5 beats Where it stands The Nancy Grace Roman Space Telescope Active Did the new NASA space telescope launch and does it work? Where it stands · Oct 18, 2026 The Nancy Grace Roman Space Telescope launched August 31, and NASA has extended its planned mission life from 10 to 22 years after finding it carries about double the expected propellant. Its Wide Field Instrument has now passed its commissioning checks, with image quality nearly 30 percent better than predicted. These were engineering tests, and no science images have been returned yet. Latest · Nov 12, 2026 Live Science reported that the Nancy Grace Roman Space Telescope is about 85% of the way to its working position at Lagrange point 2 and is due there in under two weeks. Near-perfect rocket burns saved more than a decade's worth of fuel, and instrument commissioning during the trip has gone without a hitch. 10 beats 0 of 1 promise kept, 1 open Where it stands What Enceladus's plume is made of Active What Enceladus's plume is made of Where it stands · Oct 5, 2026 Cassini detected 961 salt-rich ice grains from Enceladus with very different chemistry from one another. Lab freezing experiments show that slow-cooling droplets sort their salts, so a single ocean can produce many kinds of grain. How closely the lab process matches what happens in the moon's vents is not yet established. Latest · Nov 12, 2026 Nature published a paper reporting that salty grains in Saturn's outermost ring formed from the slow freeze of plumes from the moon Enceladus. 3 beats Where it stands Is Mars still geologically alive? Active Is Mars still geologically alive? Where it stands · Nov 8, 2026 The ExoMars Trace Gas Orbiter spotted hydrogen chloride spikes near Alba Mons, where researchers also found new fissures thousands of feet long, Futurism reported. Researchers read this as evidence that Mars kept enough internal heat for volcanic activity until recently. Whether the volcanoes are active today is not established. Latest · Nov 8, 2026 Futurism reported that the ExoMars Trace Gas Orbiter spotted hydrogen chloride spikes near Alba Mons, where researchers also found new fissures thousands of feet long. The findings are read as evidence that Mars kept enough internal heat for volcanic activity until recently. 1 beat Where it stands IceCube and the neutrino sky Active IceCube and the neutrino sky Where it stands · Oct 8, 2026 IceCube was the first detector to find neutrinos coming from deep space, after decades of research into these elusive particles. Nature's roundup of the 2026 Nobel Prizes included a hunter of ghost particles. What sources the neutrinos trace back to is still being worked out. Latest · Nov 3, 2026 ScienceDaily reported that IceCube detected ghost particles with 10 billion times the energy of solar neutrinos. 3 beats Where it stands Japan's mission to bring back Phobos soil Active Japan's mission to bring back Phobos soil Where it stands · Oct 20, 2026 Japan's MMX mission has launched, starting a round trip meant to return Phobos soil to Earth by 2031, the first such return from that moon. The spacecraft is due to reach Mars in August 2027. It is not yet known whether it can land on and sample Phobos's weak-gravity surface. Latest · Oct 22, 2026 Good News Network reported that MMX lifted off on an H3 rocket from Tanegashima on October 19 as a five-year, $578 million effort led by JAXA with NASA, CNES, DLR and ESA. A French-German rover named Idefix is to land first and scout a safe spot on Phobos. The lander is then meant to spend about two hours on the surface and collect at least 10 grams of material before the probe leaves Mars in 2030. 3 beats 0 of 2 promises kept, 2 open Where it stands The undruggable protein problem Active Can drugs finally hit the proteins once called undruggable? Where it stands · Sep 4, 2026 The FDA approved daraxonrasib, sold as Rasonque, for advanced pancreatic cancer in August after a trial found patients lived a median of 13.2 months versus 6.7 months on standard chemotherapy. It works around KRAS, the gene behind more than 90 percent of pancreatic tumors and long thought too smooth a surface for any drug to grip, by binding a molecule called cyclophilin A. Whether tumors develop resistance to it the way they do to chemotherapy is not yet known. Latest · Oct 3, 2026 Scripps researchers built a small computer-designed protein that binds the membrane-spanning region of TLR4, an inflammation-linked immune receptor with no FDA-approved drug aimed squarely at it, and blocks its inflammatory signaling. 4 beats Where it stands A gut bacterium that hunts tumors Active Can a gut bacterium be used to attack tumors? Where it stands · Sep 4, 2026 A team at the Japan Advanced Institute of Science and Technology screened 45 bacterial strains from the guts of tree frogs, newts and lizards and found one, Ewingella americana, that cleared colorectal tumors in mice. A single intravenous dose produced a 100 percent complete response rate, beating both a checkpoint-inhibitor drug and the chemotherapy used for comparison. It has been tested in mice, in one cancer type, and no person has received it. Latest · Sep 21, 2026 ScienceAlert reported that a separately engineered probiotic wiped out 43 percent of colorectal tumors in mice, a second bacterial approach targeting the same cancer type as the Ewingella americana work. 6 beats Where it stands Restoring sight without an implant Active Can eyesight be restored without an implant? Where it stands · Sep 9, 2026 A consortium led by the Institute for Bioengineering of Catalonia made light-activated compounds, named prosthe6, that restored light perception and visually guided behavior in blind mice and zebrafish by waking retinal circuitry that survives after photoreceptors die, and two variants worked simply as eye drops, no injection or implant needed. Separately, a blind woman injected with her own muscle mitochondria saw her pupils respond to light again, though the effect faded after about four weeks. Macular degenerati Latest · Sep 9, 2026 The Optimist Daily reported that IBEC's light-activated eye drop compounds are named prosthe6, with two variants, prosthe6-12 and prosthe6-15, working as simple eye drops with no injection or implant; in blinded zebrafish larvae and mice modeling macular degeneration and retinitis pigmentosa, the drops restored reflexive eye movements and light-avoidance behavior within days at light levels no stronger than an overcast afternoon. 3 beats Where it stands Clean air zones show up in children's lungs Active Do clean air zones actually improve children's lungs? Where it stands · Sep 4, 2026 London's Ultra Low Emission Zone is the first clean air scheme shown to change how children's lungs grow, not just what the monitors read. A Lancet Public Health study of 3,414 school children found better lung growth inside the zone five years after roadside nitrogen dioxide fell 54 percent, and the share of Central London children with impaired lung function fell from 14 percent to 9 percent. Luton is an imperfect comparison town, and no other city has shown the same. Latest · Sep 1, 2026 Queen Mary University researchers reported that annual lung capacity gains in London's ultra low emission zone children rose to 233 milliliters a year, overtaking the 223 milliliters recorded in the Luton comparison group that had started out with cleaner air, and the share of Central London children with impaired lung function fell from 14 percent to 9 percent over the same period. 3 beats Where it stands Ghost ancestor lineages in human DNA Active Are there lost human ancestors hiding in our DNA? Where it stands · Sep 4, 2026 A team led by Priya Moorjani at UC Berkeley scanned more than 500 modern human genomes and found two previously unknown archaic lineages that interbred with our ancestors, one of which left DNA in every person alive today, contributing about 1% of the genome. A Science study using the same fossil-free method suggests those lineages are Homo heidelbergensis and Homo erectus. What the surviving gene regions actually do in people has not been established. Latest · Aug 3, 2026 A Science study using a new fossil-free detection method found the ghost lineage carried by everyone alive today likely belongs to Homo heidelbergensis, while the super-archaic lineage found in Oceanian populations likely belongs to Homo erectus, and both archaic gene regions concentrate in parts of the genome tied to immune function and metabolism. 3 beats Where it stands The quantum advantage race Active Can quantum computers actually beat regular computers yet? Where it stands · Sep 4, 2026 Classical hardware keeps catching up. Joseph Tindall and Miles Stoudenmire at the Flatiron Institute used tensor networks to reproduce on a personal laptop results a team had claimed required a quantum computer to model. On the hardware side, a group in Austria and Munich entangled two distant qubits automatically using a shared low-energy microwave bath, tested across about 20 inches of cable. Whether that entanglement holds at any useful distance is untested. Latest · Jul 29, 2026 A team at the Institute of Science and Technology Austria and the Technical University of Munich confirmed a 20-year-old theory by entangling two distant qubits automatically using a shared low-energy microwave bath, with no active photon-matching required, testing it across about 20 inches of cable. 2 beats Where it stands Building a living cell from parts Active Can scientists build a living cell from scratch? Where it stands · Sep 4, 2026 The minimal genome work has held up: JCVI-syn3.0 runs on just 473 genes, and a synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, though only about 30 percent still carried DNA after five generations. The synthetic yeast consortium finished all 16 chromosomes about five years past the 2018 target it set itself. Combining them into a single fully synthetic yeast cell is still unfinished. Latest · Jul 2, 2026 A synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, with about 30 percent still carrying DNA after five generations. 8 beats 0 of 1 promise kept Where it stands Our ancient relatives, still in our genes Active Does Neanderthal and Denisovan DNA still shape our immune systems? Where it stands · Sep 4, 2026 Genes picked up from Neanderthals and Denisovans are still doing work in modern immune systems, sometimes raising disease risk and sometimes lowering it. One Neanderthal stretch on chromosome 12 lowers the risk of severe COVID-19 by around 22 percent, and researchers have now catalogued more than 3,000 Denisovan variants active in modern immune cells. Which ancient pathogens drove those variants is still unknown. Latest · Jun 19, 2026 Researchers catalogued more than 3,000 Denisovan genetic variants active in modern immune cells, with some Papua New Guinean populations carrying up to about 5 percent Denisovan DNA. 7 beats Where it stands

Technology & Innovation 10

Brain implants leave the lab Moved this week Can brain implants give paralyzed people movement and speech back? Where it stands · Sep 15, 2026 Brain-computer interfaces are starting to restore more than one channel of expression at once. A UCSF team led by Edward Chang showed three paralyzed patients could control a full-body avatar that spoke and gestured together, with two of them managing both in real time, while Feinstein Institutes researchers separately reported a double neural bypass raising one patient's arm strength by up to 86 percent after 35 weeks of training. These remain single-digit patient counts inside research trials, and how long any of Latest · Nov 21, 2026 Trial participants who have had brain implants, led by Ian Burkhart, published 13 recommendations on post-trial care, informed consent and neural data privacy for startups, researchers and regulators, STAT reported. 9 beats 0 of 1 promise kept, 1 open Where it stands CAR T cell therapy takes aim at solid tumors Moved this week Can engineered immune cells work against solid tumors? Where it stands · Sep 23, 2026 CAR T cell therapy is showing durable results against solid tumors on more than one front. Beyond the GPNMB-targeted glioblastoma work, a Baylor College of Medicine team used a 3-year-old boy's own reprogrammed immune cells to clear metastatic liver cancer that had resisted surgery and chemotherapy twice, and he remained cancer-free a year later. Both results rest on a single patient each, so durability and repeatability in a larger group are still unproven. Latest · Nov 19, 2026 UCSF's B-SYNC CAR-T cells, engineered to switch on only inside the brain, cleared diffuse midline glioma in every mouse tested and blocked tumors from returning, Good News Network reported. Human trials could start as early as April 2027. 7 beats 0 of 2 promises kept, 2 open Where it stands Starship reaches orbit Moved this week Starship reaches orbit Where it stands · Nov 15, 2026 Starship flight 15 ended with the tower arms catching Ship 42 after 14 orbits, the first catch of a ship returning from orbit. The booster catch was called off after a fuel-system alarm and it splashed down in the Gulf. Interesting Engineering reported the heat shield still needs more development before reuse with minimal refurbishment, so routine turnaround is not yet shown. Latest · Nov 15, 2026 Universe Today, Ars Technica and Interesting Engineering reported that on November 14 the tower arms caught Ship 42, the Starship upper stage, after it circled the Earth 14 times and released 26 more Starlink satellites. It was the first catch of a ship returning from orbit. The booster's own catch had been called off the day before after a fuel-system alarm, and it splashed down in the Gulf. 2 beats Where it stands The clean-energy tipping point Active Is clean energy winning? Where it stands · Sep 15, 2026 Solar generated more US electricity than coal for the first time in the country's history, and global solar capacity reached roughly 3 terawatts in early 2026, with wind and solar together supplying 22 percent of global electricity by April 2026. Cheap panels, mostly made in China, have pushed solar into millions of individual homes, small businesses and factories, cutting bills and bringing reliable power to places grids never reached. Grids engineered for one-way power flow are struggling to keep pace with that s Latest · Nov 10, 2026 Phys.org reported on the 2026 Global Carbon Budget, which projects fossil CO2 emissions of 38.2 billion metric tons this year, down 0.4% and the first fall since 2020. The authors say two-thirds of the rise in global energy demand is being met by solar, wind and electric vehicles, though part of the dip comes from the energy shock of the Iran conflict. 17 beats 0 of 2 promises kept, 2 open Where it stands Perseverance and the off-world driving record Active Perseverance and the off-world driving record Where it stands · Oct 24, 2026 ScienceAlert reported that NASA's Perseverance has broken the off-world driving record while mostly steering itself. Details of the distance and the autonomy involved are not yet recorded here. Whether the same approach scales to harder terrain and future missions is not known. Latest · Nov 3, 2026 ScienceDaily reported that NASA's Perseverance Mars rover broke a historic driving record after traveling 28 miles. 2 beats Where it stands Anthropic's AI biolab finds a new CRISPR-like system Active Anthropic's AI biolab finds a new CRISPR-like system Where it stands · Sep 26, 2026 Anthropic's AI biolab reported that agents mining viral and phage genomes for new biology surfaced a previously undescribed CRISPR-like DNA system, an early sign that an AI research agent can produce a genuinely novel finding rather than just synthesize known results. Nature covered the find on 2026-09-26, noting outside researchers still need to confirm it functions as claimed. It is not yet known how many of the AI biolab's other proposed discoveries will hold up under wet-lab testing. Latest · Sep 26, 2026 Nature reported that Anthropic's AI biolab, mining viral and phage genomes for new biology, identified a previously unknown CRISPR-like DNA system in viruses. 1 beat Where it stands Europe's push into private orbital launch Active Europe's push into private orbital launch Where it stands · Sep 11, 2026 Isar Aerospace's Spectrum rocket launched from Andoya Spaceport in Norway on its second attempt and released five CubeSats and a technology experiment into orbit, the first successful orbital launch by a privately built European rocket. The company has five more Spectrum rockets in production, a factory near Munich nearing completion, and roughly 10 billion euros in customer deals lined up. Scaling to the 40 launches a year the company hopes for is a much larger, unproven engineering and manufacturing challenge. Latest · Sep 12, 2026 Ars Technica reported that Isar Aerospace, founded in 2018 by three students at a German university, spent roughly $1 billion in private financing over eight years before Spectrum's successful second launch attempt, and that satellite operator Astroscale had already signed a launch contract with Isar before the rocket ever reached orbit. 2 beats Where it stands AI's disputed rise in pure mathematics Active AI's disputed rise in pure mathematics Where it stands · Sep 12, 2026 AI systems keep producing claimed proofs of hard mathematical problems, but the field is increasingly divided over whether to trust them. The world's top 25 Fields Medalists have warned that machine-generated proofs are undermining rigor in the hardest areas of math, and OpenAI's latest claimed result triggered fresh disputes over credit, ethics and privacy. It is still unclear how much of AI's contribution can be verified independently of the companies making the claims. Latest · Sep 12, 2026 The world's top 25 Fields Medalists warned that machine-generated proofs are undermining rigor in mathematics' hardest problems, while OpenAI claimed another major mathematical result amid disputes over credit, ethics and privacy. 1 beat Where it stands Humanoid robots enter the operating room Active Can humanoid robots perform surgery? Where it stands · Sep 4, 2026 A UCSD team completed the first surgeries done by teleoperated humanoid robots, including a gallbladder removal with a surgeon assisting one robot and a second procedure with two robots working together, both on large nonprimate animals. The robots stand five feet tall and weigh 27 kilograms, against the hundreds of kilograms of conventional systems. The Nature study said plainly that precision, force sensing in soft tissue and clinical safety remain unsolved. Latest · Jul 9, 2026 A UCSD team completed the first surgeries using teleoperated humanoid robots, including a gallbladder removal with a surgeon assisting a single robot and a second procedure with two robots working together on large nonprimate animals. The peer-reviewed study in Nature evaluated the platform across benchtop characterization, dry-lab user studies, and live porcine trials, and was explicit that precision, force sensing in soft tissue, and clinical safety are challenges that remain unsolved before any move toward human patients. 6 beats Where it stands A vaccine for coronaviruses we have not met Active Can one vaccine cover coronaviruses that have not appeared yet? Where it stands · Sep 4, 2026 A University of Cambridge group used AI to find the parts of the sarbecovirus family, which includes SARS and COVID-19, that a virus cannot mutate away without losing fitness, and built a fridge-stable DNA vaccine around them that has entered human trials. The older mosaic-8 nanoparticle from Oxford and Caltech, promised a first human trial in 2024, still had no confirmed first dosing in the public record as of mid-2026. No broad vaccine has yet shown it protects anyone. Latest · Jul 8, 2026 Researchers at the University of Cambridge used AI to scan genetic data from thousands of sarbecoviruses, identify conserved targets a virus is unlikely to mutate without losing fitness, and design a DNA vaccine stable without refrigeration and delivered via needle-free high-pressure liquid injection. The vaccine entered human trials for the first time, aiming to protect against the entire sarbecovirus family including strains that do not yet exist. 6 beats 0 of 2 promises kept, 1 open Where it stands

Solutions & Good News 9

Foie gras bans reach the ballot box Moved this week Foie gras bans reach the ballot box Where it stands · Nov 17, 2026 On November 3, 73 percent of DC voters and 66 percent of Denver voters backed foie gras sale bans. DC's ban takes effect in July 2027, and the country's largest foie gras producer, Hudson Valley Farms, told Axios it is considering legal challenges. Whether a lawsuit is filed, and whether it succeeds, is not known. Latest · Nov 21, 2026 Vox reported that barns full of birds from America's biggest foie gras company burned down. Separately, Vegan Food & Living reported that the UK government scrapped its promised foie gras import ban to secure an EU trade deal. 2 beats Where it stands Forever chemicals falling in England's rivers Moved this week Forever chemicals falling in England's rivers Where it stands · Nov 19, 2026 Over 10 years, PFOS fell 30 percent and PFOA 29 percent in English river water, and levels in freshwater fish dropped 49 percent. The Environment Agency cautions that the total amount of these chemicals in the environment has probably not changed much. Whether the declines continue is not yet known. Latest · Nov 19, 2026 The Optimist Daily reported that over 10 years PFOS fell 30 percent and PFOA 29 percent in English river water, and levels in freshwater fish dropped 49 percent. The Environment Agency cautioned that the total amount in the environment has probably not changed much. 1 beat Where it stands Beavers rewilding drought-stressed rivers Active Beavers rewilding drought-stressed rivers Where it stands · Sep 28, 2026 Utah State University began relocating nuisance beavers into the drought-stressed Price River in 2019, and six years later the river holds its healthiest water levels in years with thriving fish populations. The project has since spread to other Utah watersheds. It is not yet documented how the approach performs outside Utah or under harsher drought conditions. Latest · Nov 4, 2026 Good News Network reported that NatureScot granted a license on October 30 to Trees for Life and the Beaver Trust to release up to 15 beaver families over three years in the River Ness catchment, which includes Loch Ness. Beavers were last recorded there in 1526 and 1527, and more than 73% of consultation respondents expressed support. 3 beats 0 of 1 promise kept, 1 open Where it stands Healing bleached coral by touch Active Healing bleached coral by touch Where it stands · Oct 18, 2026 Stanford researchers reported in Science Advances that bleached coral fragments touching healthy clones of the same colony recovered fully in seven weeks, with tissue recovery starting in three days, while fragments held a few millimeters apart died. The work was done on fragments in a tank, between genetically identical clones. Whether it can work in a nursery or on an open reef is not known. Latest · Oct 29, 2026 The Bright Side reported more detail on the Science Advances experiment: Danny Collins, a PhD student in Stephen Palumbi's lab, ran ten pairs of a healthy and a bleached fragment cut from the same animal. All five touching pairs recovered and all five pairs held a few millimetres apart died. Michael Sweet at the University of Derby noted that aquarists already knew algae can move between corals, and said what is new is a controlled paper. 2 beats Where it stands Highway bridges for wildlife Active Highway bridges for wildlife Where it stands · Oct 17, 2026 Colorado's I-25 wildlife overpass, the largest in North America, cut animal-vehicle collisions on its stretch by 91 percent in its first ten months, with elk, moose, pronghorn and bears using it. The figure covers the whole system of five underpasses, fencing and the bridge, not the bridge alone. Ten months is a short record, and it is not yet known whether the drop holds over several years or repays the cost. Latest · Oct 21, 2026 The Bright Side reported that Colorado's I-25 grass overpass, opened in December 2025, cost about $15 million against a $30 million budget. State officials told The Colorado Sun that drivers have hit two animals in roughly ten months. The piece noted that the often-quoted 91 percent collision drop belongs to the earlier phase of fences and underpasses, not the bridge deck alone. 4 beats 0 of 2 promises kept, 2 open Where it stands Keeping elephants and people apart in North Bengal Active Keeping elephants and people apart in North Bengal Where it stands · Oct 21, 2026 Razor-wire fencing in the assessed North Bengal tea estates fell from about 134.7 km in 2019 to 34.8 km in 2026, a 74.2 percent cut, after years of talks between conservationists and estate managers. Earlier coverage tracked early-warning alert tools for elephant conflict. It is not yet known whether the changes have reduced conflict deaths or crop loss. Latest · Oct 21, 2026 The Better India reported that razor-wire fencing in the assessed North Bengal tea estates fell from about 134.7 km in 2019 to 34.8 km in 2026, a 74.2 percent cut, after years of talks between conservationists and estate managers. 1 beat Where it stands Aldabra's giant tortoise comeback Active Aldabra's giant tortoise comeback Where it stands · Oct 12, 2026 The Seychelles Islands Foundation and the University of Exeter estimated almost 183,000 adult and sub-adult giant tortoises on Aldabra Atoll from counts made between 2018 and 2022, the highest figure on record and the first update to the 100,000 figure cited since the late 1990s. The population looked relatively stable over those years, so the number is a new baseline, not a growth curve. Whether removing feral cats and black rats would lift the remaining limits on growth is not known. Latest · Oct 12, 2026 The Seychelles Islands Foundation and the University of Exeter analyzed five years of counts from 2018 to 2022 and estimated almost 183,000 adult and sub-adult giant tortoises on Aldabra Atoll, the highest figure on record and the first update to the 100,000 figure cited since the late 1990s. The team modeled animals it could not see in dense vegetation, and the population looked relatively stable over the study years. 1 beat Where it stands Smell-based pesticide repellents for honeybees Active Smell-based pesticide repellents for honeybees Where it stands · Sep 28, 2026 UC Riverside's Anandasankar Ray screened more than 50 million compounds by machine learning for odors bees avoid, narrowed the field to about 130 candidates, and confirmed in field trials that seven reliably kept foraging bees away from treated combs without harming them. A patent application has been filed, but the compounds have not yet been deployed commercially. Latest · Sep 28, 2026 UC Riverside's Anandasankar Ray built a machine-learning model that screened more than 50 million compounds for bee-repellent odors, narrowed the field to about 130 candidates, and confirmed in field trials with freely foraging bees that seven of the compounds reliably kept bees away from treated combs without harming them, with a patent application already filed. 1 beat Where it stands Bringing apex predators back from the brink Active Are wolves and tigers coming back to the wild? Where it stands · Sep 4, 2026 North Carolina's wild red wolf population, down from around 120 to 130 animals in 2011 to fewer than 30, produced four litters and 23 pups this year, with roughly 12 to 16 expected to survive their first months. In Kazakhstan, a female Amur tiger named Hope was released into an unfenced reserve after a decade of reforestation and rebuilding of prey species. Whether this year's pups live long enough to rebuild the population is not yet known. Latest · Aug 18, 2026 One Green Planet reported that North Carolina's wild red wolf population, which collapsed from around 120 to 130 animals in 2011 to fewer than 30 after gunshots, vehicle strikes and coyote hybridization, produced four litters and 23 pups this year, with roughly 12 to 16 expected to survive their first months. 2 beats Where it stands

Psychology & Behavioral Science 7

Psilocybin's move into the clinic Moved this week Is psilocybin turning into real medicine? Where it stands · Nov 17, 2026 Compass Pathways has completed its FDA application for COMP360 psilocybin in treatment-resistant depression after two positive Phase 3 trials with more than 1,000 participants. Helus Pharma separately announced a positive Phase 3 for HLP003, a psilocin derivative, in 222 adults, with remission of 50.9% versus 18.2% on placebo at week 6. Both sets of results come from the companies, and it is not known whether the FDA will approve either drug or how durable the benefit is. Latest · Nov 17, 2026 Helus Pharma announced topline results from APPROACH, a Phase 3 trial of HLP003, a deuterated form of psilocin added to a stable antidepressant in 222 adults with major depressive disorder. At week 6, depression scores fell 19.5 points with HLP003 and 11.9 with placebo, a placebo-adjusted difference of 7.6 points, and remission was 50.9% versus 18.2%. Three treatment-related serious adverse events occurred, and the results are company-announced, not yet peer reviewed. 33 beats 0 of 2 promises kept, 2 open Where it stands Personalized magnetic stimulation for PTSD Active Personalized magnetic stimulation for PTSD Where it stands · Nov 5, 2026 The Optimist Daily reported that a personalized magnetic stimulation therapy produced 68 percent remission for PTSD in its trial. A 2020 review put the ceiling for approved medications at 10.9 percent, but these are separate studies, not a head-to-head comparison. Whether the remissions last, and how the therapy compares directly with existing treatments, is not yet known. Latest · Nov 10, 2026 Psychology Today reported a randomized study of 73 veterans in which ten sessions over two weeks of stimulation personalized to each person's alpha rhythm were linked to a 34% drop in PTSD severity and 44% fewer sleep disturbances. The trial is small. 2 beats Where it stands Speech as a clock for the aging brain Active Speech as a clock for the aging brain Where it stands · Oct 28, 2026 A Science Advances study of nearly 3,000 adults across Latin America used automated analysis of short voice recordings to produce a speech age that ran older in people with dementia. The gap between speech age and real age was linked to brain-scan and DNA-based aging measures, a blood marker of Alzheimer's, and lifetime social hardship. The study reports links across a large group, not a cutoff that diagnoses any one person. Latest · Oct 28, 2026 PsyPost reported a Science Advances study of nearly 3,000 adults across Latin America, led by Hernan Hernandez of the Latin American Brain Health Institute. A speech age from short recordings ran older in people with dementia and tracked brain-scan and DNA-based aging measures and a blood marker of Alzheimer's. 1 beat Where it stands Early-life sugar and the aging brain Active Early-life sugar and the aging brain Where it stands · Oct 24, 2026 People conceived during Britain's sugar rationing, which gave children under two no sugar ration at all, had a 27% lower dementia risk and 46% lower Alzheimer's risk than those conceived after it ended, PsyPost reported from UK Biobank data. It is a natural experiment, not a trial, and the brain-aging difference was only slight. Whether sugar itself drives the difference, rather than other changes that came with the end of rationing, is not known. Latest · Oct 24, 2026 PsyPost reported that people conceived during Britain's 1942 to 1953 sugar rationing, which gave children under two no sugar ration at all, had a 27% lower dementia risk and 46% lower Alzheimer's risk than those conceived after it ended, with slightly slower brain aging decades later, in UK Biobank data. 1 beat Where it stands The brain's two separate lineages Active The brain's two separate lineages Where it stands · Sep 23, 2026 A Stanford Medicine study published September 18 in Nature Neuroscience found, using both mouse and human stem cells, that the forebrain and midbrain arise from one population of neural progenitor cells and the hindbrain from an entirely separate one, each carrying a distinct chromatin landscape from remarkably early in development. This overturns the long-standing assumption of one progenitor lineage that diverges late. It is not yet known what this means for how the brain recovers from injury or why certain condi Latest · Oct 17, 2026 Live Science reported on the Stanford finding in mouse embryos that the front and back of the brain come from two separate cell populations. The coverage said the split may explain why hindbrain neurons have been so hard to grow in the lab. 3 beats Where it stands Metabolic interventions for mental illness Active Can changing your diet ease schizophrenia or bipolar disorder? Where it stands · Sep 4, 2026 A UCSF randomized controlled trial found a ketogenic diet reduced clinical symptoms of schizophrenia and bipolar disorder, with the gains holding after researchers controlled for weight loss. In that trial 83 percent of patients maintained ketosis through the one-month primary phase, and higher blood ketone levels tracked with sharper drops in depression scores. A McLean Hospital and Harvard trial in first-episode bipolar disorder is not due to report until late 2027. Latest · Oct 1, 2026 Psychiatric Times ran pieces on ketogenic metabolic therapy as an adjunct in serious mental illness and on metabolic psychiatry integrating nutritional and pharmacological interventions. 7 beats 0 of 1 promise kept, 1 open Where it stands Cash aid and children's biological aging Active Cash aid and children's biological aging Where it stands · Sep 22, 2026 Researchers with the Baby's First Years project found that children of mothers given a larger unconditional monthly cash gift were aging more slowly, measured by DNA methylation using the DunedinPACE algorithm, than children in a comparison group receiving a smaller amount. The effect showed up only in the children, not in the mothers who received the same cash. It is the first evidence that relieving poverty, even partially, can slow the biological aging clock poverty is known to speed up, though why the effect sp Latest · Sep 22, 2026 Researchers with the Baby's First Years project found that children of mothers given the larger monthly unconditional cash gift showed slower biological aging by the DunedinPACE DNA methylation measure than children in the comparison group, an effect that appeared in the children but not the mothers. 1 beat Where it stands

Plant-Based & Vegan 4

Cultivated chicken reaches restaurant menus Moved this week Cultivated chicken reaches restaurant menus Where it stands · Nov 19, 2026 Upside Foods' cultivated chicken is on menus at eight California restaurants plus corporate and college dining programs, at prices of $12 to $19 a dish. New 20,000-liter tanks give it capacity for more than 1 million pounds a year, according to the company. It is available in California only, and Meatable and Believer Meats have stopped operating. Latest · Nov 19, 2026 VegNews reported that Upside Foods' cultivated chicken is on menus at eight California restaurants, with dishes priced from $12 to under $20. New 20,000-liter cultivator tanks give the company capacity for more than 1 million pounds a year. In 2017 one pound cost around $9,000 to make. 1 beat Where it stands The gap between opinion and factory farming Active Is farm animal welfare policy catching up with public opinion? Where it stands · Sep 4, 2026 The gap is closing in places and widening in others. Brazil banned both the production and sale of foie gras, and the US share of cage-free eggs rose from under 20 percent in 2018 to 45.7 percent by July 2025 as producers moved to keep selling into California under Proposition 12. Over the same stretch JBS, the world's largest meat company, dropped its net-zero and deforestation commitments, and most farmed animals are still raised on factory farms. Latest · Oct 31, 2026 The UK government opened an eight-week consultation on phasing out CO2 stunning of pigs, proposing a two-to-three-year transition to more humane methods. Compassion in World Farming says CO2 stunning rose from 52% of UK pigs in 2013 to 90% in 2025. The independent Animal Welfare Committee had earlier found significant evidence that CO2 causes avoidable pain and fear and recommended ending it within five years at most. This is a consultation, not a law. 14 beats Where it stands Ending the killing of male chicks Active Ending the killing of male chicks Where it stands · Sep 19, 2026 In-ovo sexing is running commercially in the United States and Brazil, and Canada has developed methods that can determine sex as early as day four of incubation. Norway adopted the technology in 2023 and has committed to ending chick culling entirely by July 2027, Switzerland began its own transition in 2025, and Germany and France have already banned culling outright. It is not yet clear whether larger egg-producing countries like the US and Brazil will commit to a phase-out timeline of their own rather than only Latest · Sep 19, 2026 Mercy For Animals reported that Norway adopted in-ovo chick sexing in 2023 and has committed to phasing out chick culling entirely by July 2027, that Switzerland began its own transition to the technology in 2025, and that more than 70 percent of surveyed US consumers said the industry should find an alternative to killing day-old male chicks. 2 beats 0 of 1 promise kept, 1 open Where it stands Engineering myoglobin for plant-based meat Active Can plant-based meat get real meat flavor without an animal? Where it stands · Sep 4, 2026 Belgian startup Paleo engineers a food yeast to make bioidentical myoglobin, the iron-rich protein behind meat's color and savory flavor, and raised a 2 million euro round to fund US and Canadian regulatory filings and formulation trials, after cutting production costs 613-fold since 2020. An Imperial College London team separately got lettuce and tobacco plants to make myoglobin at roughly a tenth of beef's level. Neither has cleared a regulator or reached a shelf. Latest · Sep 2, 2026 Belgian startup Paleo raised a 2 million euro ($2.3 million) round led by Beyond Impact to fund US and Canadian regulatory filings and formulation trials for its fermentation-made, bioidentical myoglobin, after cutting production costs 613-fold since 2020. 2 beats Where it stands

Every beat was reported in our daily letter on its date and links onward to the primary study. A tracker is opened only when a story comes back a second time, never for a single day's headline. Every promise stays on the record until it is kept, slips, or passes its own date with no word, and silence is reported as silence, never as failure.

The trackers move every morning.

The day's real progress in science, medicine and beyond, every morning. When a tracker advances, you'll already know. Free, every day.